Literature DB >> 17903032

Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy.

Beatriz Pinar1, Pedro Carlos Lara, Marta Lloret, Elisa Bordón, María Isabel Núñez, Mercedes Villalobos, Rosa Guerrero, J D Luna, J M Ruiz de Almodóvar.   

Abstract

This 14-year-long study makes a novel contribution to the debate on the relationship between the in vitro radiosensitivity of peripheral blood lymphocytes and normal tissue reactions after radiation therapy. The aims were (1) to prospectively assess the degree and time of onset of skin side effects in 40 prospectively recruited consecutive patients with locally advanced breast cancer treated with a hyperfractionated dose-escalation radiotherapy schedule and (2) to assess whether initial radiation-induced DNA damage in peripheral blood lymphocytes of these patients could be used to determine their likelihood of suffering severe late damage to normal tissue. Initial radiation-induced DNA double-strand breaks (DSBs) were assessed in peripheral blood lymphocytes of these patients by pulsed-field electrophoresis. Acute and late cutaneous and subcutaneous toxicity was evaluated using the Radiation Therapy Oncology Group morbidity score. A wide interindividual variation was observed in toxicity grades and in radiation-induced DNA DSBs in peripheral blood lymphocytes (mean 1.61 +/- 0.76 DSBs/Gy per 200 MBp, range 0.63- 4.08), which were not correlated. Multivariate analysis showed a correlation (P < 0.008) between late toxicity and higher prescribed protocol dose (81.6 Gy). Analysis of the 29 patients referred to 81.6 Gy revealed significantly (P < 0.031) more frequent late subcutaneous toxicity in those with intrinsic sensitivity to radiation-induced DNA DSBs of >1.69 DSBs/Gy per DNA unit. Our demonstration of a relationship between the sensitivity of in vitro-irradiated peripheral blood lymphocytes and the risk of developing late toxic effects opens up the possibility of predicting normal tissue response to radiation in individual patients, at least in high-dose non-conventional radiation therapy regimens.

Entities:  

Mesh:

Year:  2007        PMID: 17903032     DOI: 10.1667/RR0746.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  12 in total

1.  Molecular biomarkers in the decision of treatment of cervical carcinoma patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

Review 2.  New biological markers in the decision of treatment of head and neck cancer patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

3.  Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.

Authors:  Mercedes Zurita; Pedro C Lara; Rosario del Moral; Blanca Torres; José Luis Linares-Fernández; Sandra Ríos Arrabal; Joaquina Martínez-Galán; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

4.  Radiation induced apoptosis and initial DNA damage are inversely related in locally advanced breast cancer patients.

Authors:  Beatriz Pinar; Luis Alberto Henríquez-Hernández; Pedro C Lara; Elisa Bordon; Carlos Rodriguez-Gallego; Marta Lloret; Maria Isabel Nuñez; Mariano Ruiz De Almodovar
Journal:  Radiat Oncol       Date:  2010-09-24       Impact factor: 3.481

Review 5.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

6.  In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.

Authors:  Thorsten Petrich; Zekiye Korkmaz; Doris Krull; Cornelia Frömke; Geerd J Meyer; Wolfram H Knapp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

7.  Combined low initial DNA damage and high radiation-induced apoptosis confers clinical resistance to long-term toxicity in breast cancer patients treated with high-dose radiotherapy.

Authors:  Luis Alberto Henríquez-Hernández; Ruth Carmona-Vigo; Beatriz Pinar; Elisa Bordón; Marta Lloret; María Isabel Núñez; Carlos Rodríguez-Gallego; Pedro C Lara
Journal:  Radiat Oncol       Date:  2011-06-06       Impact factor: 3.481

8.  Multiple low-dose radiation prevents type 2 diabetes-induced renal damage through attenuation of dyslipidemia and insulin resistance and subsequent renal inflammation and oxidative stress.

Authors:  Minglong Shao; Xuemian Lu; Weitao Cong; Xiao Xing; Yi Tan; Yunqian Li; Xiaokun Li; Litai Jin; Xiaojie Wang; Juancong Dong; Shunzi Jin; Chi Zhang; Lu Cai
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

9.  Human mesenchymal stem cells enhance the systemic effects of radiotherapy.

Authors:  Virgínea de Araújo Farias; Francisco O'Valle; Borja Alonso Lerma; Carmen Ruiz de Almodóvar; Jesús J López-Peñalver; Ana Nieto; Ana Santos; Beatriz Irene Fernández; Ana Guerra-Librero; María Carmen Ruiz-Ruiz; Damián Guirado; Thomas Schmidt; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  Oncotarget       Date:  2015-10-13

10.  Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy.

Authors:  Luis Alberto Henríquez Hernández; Pedro Carlos Lara; Beatriz Pinar; Elisa Bordón; Carlos Rodríguez Gallego; Cristina Bilbao; Leandro Fernández Pérez; Amílcar Flores Morales
Journal:  Radiat Oncol       Date:  2009-06-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.